News and Announcements
SUDA Appendix 4C For First Quarter FY2017
- Published November 01, 2016 9:57AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
31 October 2016, ASX Announcement
SUDA Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today released its Appendix 4C for the consolidated Group for the first quarter of FY2017. Receipts from customers for the period were $1.6 million, an increase of 25% from the first quarter of FY2016.
The Company reduced its net operating cash loss to $0.25 million in the first quarter compared to $0.61 million in the previous corresponding period of FY2016. Net cash used in investing activities was $0.29 million for the quarter. The cash position as at 30 September 2016 was $1.9 million.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
